First-in-human phase I study of JPH203, an L-type amino acid transporter 1 inhibitor, in patients with advanced solid tumors

[1]  Y. Kanai,et al.  Developing selective L-Amino Acid Transport 1 (LAT1) inhibitors: A Structure-Activity Relationship overview , 2019, Medical Research Archives.

[2]  J. Furuse,et al.  Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study. , 2019, The lancet. Gastroenterology & hepatology.

[3]  A. Maraveyas,et al.  ABC-06 | A randomised phase III, multi-centre, open-label study of active symptom control (ASC) alone or ASC with oxaliplatin / 5-FU chemotherapy (ASC+mFOLFOX) for patients (pts) with locally advanced / metastatic biliary tract cancers (ABC) previously-treated with cisplatin/gemcitabine (CisGem) che , 2019, Journal of Clinical Oncology.

[4]  Pascal Häfliger,et al.  The L-Type Amino Acid Transporter LAT1—An Emerging Target in Cancer , 2019, International journal of molecular sciences.

[5]  Subha Arthur,et al.  The Regulation and Function of the L-Type Amino Acid Transporter 1 (LAT1) in Cancer , 2018, International journal of molecular sciences.

[6]  Gerhard F. Ecker,et al.  Insights into the Structure, Function, and Ligand Discovery of the Large Neutral Amino Acid Transporter 1, LAT1 , 2018, International journal of molecular sciences.

[7]  P. Jutabha,et al.  Increase in L-type amino acid transporter 1 expression during cholangiocarcinogenesis caused by liver fluke infection and its prognostic significance. , 2017, Parasitology international.

[8]  H. Endou,et al.  Inhibition of l-type amino acid transporter 1 activity as a new therapeutic target for cholangiocarcinoma treatment , 2017, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.

[9]  J. Pouysségur,et al.  Genetic Disruption of the Multifunctional CD98/LAT1 Complex Demonstrates the Key Role of Essential Amino Acid Transport in the Control of mTORC1 and Tumor Growth. , 2016, Cancer research.

[10]  S. Manalis,et al.  Amino Acids Rather than Glucose Account for the Majority of Cell Mass in Proliferating Mammalian Cells. , 2016, Developmental cell.

[11]  Qian Wang,et al.  L-type amino acid transport and cancer: targeting the mTORC1 pathway to inhibit neoplasia. , 2015, American journal of cancer research.

[12]  Thijs J. Hagenbeek,et al.  L-type amino-acid transporter 1 (LAT1): a therapeutic target supporting growth and survival of T-cell lymphoblastic lymphoma/T-cell acute lymphoblastic leukemia , 2014, Leukemia.

[13]  K. Suksen,et al.  Downregulation of LAT1 expression suppresses cholangiocarcinoma cell invasion and migration. , 2014, Cellular signalling.

[14]  Y. Murakumo,et al.  High expression of L-type amino acid transporter 1 as a prognostic marker in bile duct adenocarcinomas , 2014, Cancer medicine.

[15]  T. Oyama,et al.  Prognostic significance of amino-acid transporter expression (LAT1, ASCT2, and xCT) in surgically resected tongue cancer , 2014, British Journal of Cancer.

[16]  Tsutomu Yoshida,et al.  Unique and selective expression of L-amino acid transporter 1 in human tissue as well as being an aspect of oncofetal protein. , 2014, Histology and histopathology.

[17]  N. Sunaga,et al.  Clinical significance of L-type amino acid transporter 1 expression as a prognostic marker and potential of new targeting therapy in biliary tract cancer , 2013, BMC Cancer.

[18]  H. Kusuhara,et al.  Investigation of the role of transporters on the hepatic elimination of an LAT1 selective inhibitor JPH203. , 2013, Journal of pharmaceutical sciences.

[19]  N. Sunaga,et al.  Prognostic significance of L-type amino-acid transporter 1 expression in surgically resected pancreatic cancer , 2012, British Journal of Cancer.

[20]  J. Horiguchi,et al.  Correlation of L‐type amino acid transporter 1 and CD98 expression with triple negative breast cancer prognosis , 2012, Cancer science.

[21]  M. Doll,et al.  Accuracy of various human NAT2 SNP genotyping panels to infer rapid, intermediate and slow acetylator phenotypes. , 2012, Pharmacogenomics.

[22]  H. Kusuhara,et al.  Metabolism and pharmacokinetic studies of JPH203, an L-amino acid transporter 1 (LAT1) selective compound. , 2012, Drug metabolism and pharmacokinetics.

[23]  Yoshiyuki Suzuki,et al.  High expression of L‐type amino‐acid transporter 1 (LAT1) in gastric carcinomas: Comparison with non‐cancerous lesions , 2011, Pathology international.

[24]  A. Sabbagh,et al.  Arylamine N-Acetyltransferase 2 (NAT2) Genetic Diversity and Traditional Subsistence: A Worldwide Population Survey , 2011, PloS one.

[25]  Ju-Hyun Park,et al.  Inhibition of L-type amino acid transporter modulates the expression of cell cycle regulatory factors in KB oral cancer cells. , 2010, Biological & pharmaceutical bulletin.

[26]  Y. Kanai,et al.  l‐Type amino acid transporter 1 inhibitors inhibit tumor cell growth , 2010, Cancer science.

[27]  Takashi Nakajima,et al.  Evaluation of thoracic tumors with 18F‐FMT and 18F‐FDG PET‐CT: A clinicopathological study , 2009, International journal of cancer.

[28]  Y. Kanai,et al.  L‐type amino‐acid transporter 1 as a novel biomarker for high‐grade malignancy in prostate cancer , 2009, Pathology international.

[29]  V. Ganapathy,et al.  Nutrient transporters in cancer: relevance to Warburg hypothesis and beyond. , 2009, Pharmacology & therapeutics.

[30]  N. Sunaga,et al.  Prognostic significance of L-type amino acid transporter 1 expression in resectable stage I–III nonsmall cell lung cancer , 2008, British Journal of Cancer.

[31]  Y. Kanai,et al.  Expression of LAT1 predicts risk of progression of transitional cell carcinoma of the upper urinary tract , 2007, Virchows Archiv.

[32]  T. Takayama,et al.  Expression of L‐type amino acid transporter 1 (LAT1) in esophageal carcinoma , 2005, Journal of surgical oncology.

[33]  M. Palacín,et al.  Identification of LAT4, a Novel Amino Acid Transporter with System L Activity* , 2005, Journal of Biological Chemistry.

[34]  Hong Wang,et al.  Platelet‐derived growth factor stimulates LAT1 gene expression in vascular smooth muscle: Role in cell growth , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[35]  E. Babu,et al.  Identification of a Novel System L Amino Acid Transporter Structurally Distinct from Heterodimeric Amino Acid Transporters* , 2003, Journal of Biological Chemistry.

[36]  Y. Kanai,et al.  Human L-type amino acid transporter 1 (LAT1): characterization of function and expression in tumor cell lines. , 2001, Biochimica et biophysica acta.

[37]  Eiji Takeda,et al.  Identification and Functional Characterization of a Na+-independent Neutral Amino Acid Transporter with Broad Substrate Selectivity* , 1999, The Journal of Biological Chemistry.

[38]  Eiji Takeda,et al.  Expression Cloning and Characterization of a Transporter for Large Neutral Amino Acids Activated by the Heavy Chain of 4F2 Antigen (CD98)* , 1998, The Journal of Biological Chemistry.

[39]  H. Christensen,et al.  Role of amino acid transport and countertransport in nutrition and metabolism. , 1990, Physiological reviews.